Experts meet to discuss potential of particle therapy for cancer


Monday, 13 November, 2017


Medical and health experts from across Australia and New Zealand recently convened in Adelaide to discuss the way forward for particle therapy in Australia.

SAHMRI Executive Director Professor Steve Wesselingh said, “Particle therapy uses a targeted beam of high-energy particles that can kill cancer cells without damaging surrounding healthy tissue.”

“It is a more effective treatment for a range of cancers and is especially beneficial to patients suffering from brain cancer, and infants and children whose organs are still developing.

“There are more than 70 operational particle therapy facilities around the world, and a further 40 currently under construction.

An Australian-first cancer treatment facility was the hot topic at the National Particle Therapy Symposium.

“It’s an exciting time for Australia, thanks to significant funding from the federal government earlier this year to build the country’s first particle treatment facility in South Australia by 2020.” Attendees also heard from Dr Takashi Murakami, who explained the latest developments of particle therapy for cancer treatments in Japan using carbon ion therapy and real-time motion tracking of the tumour position during treatment.

Carbon ion therapy is considered a game changer by researchers, for its ability to destroy cancer cells that are resistant to conventional radiation therapies. Japan has been using particle therapy techniques since 1994 and is considered a world leader in the field.

ANSTO’s Dr Richard Garrett said, “It’s vital to keep the communication lines open between governments, health services, research organisations, universities and Royal Colleges, in order to maximise the best possible outcomes for Australian patients.”

“We see the ideal model as a landmark national particle therapy and research centre, for both life-changing patient treatment options and research, supported by state-based proton particle therapy facilities.

“A national particle therapy and research centre would help thousands of Australians now and into the future, and we as heard from Dr Murakami, ongoing research is an important component.”

“It's time for Australia to be part of the next great wave of cancer treatment,” said Dr Garrett.

Related News

Biotech start-up to treat autoimmune diseases with hookworms

Experimental infection of human subjects with hookworms can protect against the onset of...

Merck receives Australian CRISPR nickase patent

The Australian Patent Office has allowed Merck's patent application for the use of paired...

Patient enrolment for Alzheimer's trial close to completion

Actinogen Medical has announced 75% enrolment in its Phase II clinical trial of Xanamem, its drug...


  • All content Copyright © 2018 Westwick-Farrow Pty Ltd